In Alzheimer’s treatment, an experimental drug is now offering some exciting possibilities. I’m Gabe Garza with your latest health news. A new drug designed to improve memory and cognition has now entered phase 1 clinical trials, reports the National Institutes of Health (NIH). The compound, BPN14770, was developed by an NIH program created to help the development of new neurological treatments. BPN14770 is designed to affect an enzyme that plays a role in the formation of brain cell connections. The enzyme also increases the activity of a protein tied to learning and memory in the brain. While researchers said this drug may hold promise for the treatment of Alzheimer’s disease and mild cognitive impairment, it is important to note that it is still in the very early stages of testing..